Lixisenatide - once-daily glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes

Celeste C.L. Quianzon, Mansur E. Shomali

Research output: Contribution to journalArticlepeer-review

Abstract

The glucagon-like peptide-1 receptor agonist diabetes medications have become important due to their unique features, such as their potency of glycosylated haemoglobin (HbA1C) lowering, durability of effect, glucose-depending insulin secretion resulting in a low risk of hypoglycaemia, glucagon suppression and weight loss. Lixisenatide is an investigational compound in this class, exhibits all of these features, and has some unique properties, which are highlighted in this review. The pharmacology of lixisenatide, the results of recent clinical trials investigating this agent, and its potential role in the management of type 2 diabetes will be discussed.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalEuropean Endocrinology
Volume8
Issue number1
DOIs
StatePublished - 2012

Keywords

  • Glucagon-like peptide-1 receptor agonist
  • Lixisenatide
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems

Fingerprint Dive into the research topics of 'Lixisenatide - once-daily glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes'. Together they form a unique fingerprint.

Cite this